What question did this study set out to answer?

This research aims to develop a novel assay to better predict responses to PD-1 blockade in non-small cell lung cancer (NSCLC).

CXCL10/11 and CCL19 Duplex Assay Enhances PD-L1 Immunohistochemistry in NSCLC

View Full Paper

Ask AI

Bookmark

Authors

This research demonstrates a chromogenic assay predicts response in NSCLC, indicating potential for improved immunotherapy strategies.

This research aims to develop a novel assay to better predict responses to PD-1 blockade in non-small cell lung cancer (NSCLC).
Used chromogenic in situ hybridization (cISH) to stain tumors for CXCL10/11 and CCL19.
Evaluated three scoring methods to quantify immune cell networks.
Assessed objective response rates using RECIST v1.1.
Identified 57 NSCLC patients treated with PD-(L)1 inhibitors.
37% overall response rate observed among the cohort.
Stem-immunity hub scoring displayed 100% sensitivity and improved predictive capability.

Tang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark